Results 101 to 110 of about 10,822,491 (313)

Treatment failure probability.

, 2018
Treatment failure probability.
Laura Galli (3623459), Adriano Lazzarin (237798), Silvia Nozza (319800), Daniela Mancusi (4860250), Elisabetta Carini (3623468), Andrea Poli (3623465), Alba Bigoloni (4860244), Antonella Castagna (255402), Roberta Termini (4860247), Giuseppe Tambussi (237799), Nadia Galizzi (4319092), Nicola Gianotti (3162951)   +11 more
core   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Association of high-density lipoprotein cholesterol lipid with peritoneal dialysis related peritonitis

BMC Nephrology
Background The relationship between high-density lipoprotein cholesterol (HDL-C) concentrations and the risk of peritoneal dialysis-related peritonitis (PDRP) remains unclear.
Jinsheng Mai, Yiting Wu, Yiwei Zhang, Yanjun Zhang, Sisi Yang, Xianhui Qin, Yuanyuan Zhang, Jianping Jiang   +7 more
doaj   +1 more source

Oridonin as a novel KDM5C inhibitor alleviates clonal hematopoiesis-induced cardiac aging via H3K4me3-dependent SASP suppression

Acta Pharmaceutica Sinica B
TET2-mediated clonal hematopoiesis of indeterminate potential (CHIP) is a known cardiovascular risk factor, but its role in cardiac aging and potential for pharmacological intervention remain unclear.
Xingling Chen, Qiangqiang Zhao, Linhuang Chen, Shengrong Lin, Bin Mai, Xingling He, Xiaojiao Zhang, Jiahui Chen, Sijing Li, Ziru Li, Hua Zhang, Yuehui Zhou, Xiaofang Li, Huili Liao, Taochun Ye, Shuning Sun, Zhongqi Yang, Shihao Ni, Lu Lu   +18 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

First-line antiretroviral treatment failure and associated factors in HIV patients at University of Gondar Teaching Hospital, Gondar, Northwest Ethiopia

, 2016
Mohammed Biset Ayalew,1 Dawit Kumilachew,2 Assefa Belay,3 Samson Getu,4 Derso Teju,4 Desalegn Endale,4 Yemisirach Tsegaye,4 Zebiba Wale4 1Department of Clinical Pharmacy, 2Department of Pharmaceutics, 3Department of Pharmacology, 4School of Pharmacy ...
Wale Z, Belay A, Tsegaye Y, Teju D, Kumilachew D, Ayalew MB, Getu S, Endale D   +7 more
core  

Heart Failure: Gaps in Knowledge and Failures in Treatment

PLoS Medicine, 2014
Please see later in the article for the Editors' Summary.
openaire   +4 more sources

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Autophagy and mitophagy in pancreatic β‐cell homeostasis and their involvement in diabetes pathophysiology

FEBS Letters, EarlyView.
This review focuses on the role of autophagy and mitophagy in maintaining pancreatic β‐cell function and homeostasis. We discuss how genetic defects affecting these pathways contribute to the development of type 1, type 2, monogenic, and gestational diabetes. We further explore their potential as therapeutic targets. Created in BioRender.
Yunkyeong Lee, Mingming Tong, Anna L. Gloyn   +2 more
wiley   +1 more source

Urate-lowering therapy and kidney outcomes in patients with chronic kidney disease and hyperuricemia

Signal Transduction and Targeted Therapy
Hyperuricemia is considered a modifiable risk factor for the development and progression of chronic kidney disease (CKD). There remains controversy over the effects of urate-lowering therapy (ULT) on kidney outcomes in patients with CKD and hyperuricemia.
Sheng Nie, Shiyu Zhou, Ruixuan Chen, Lantian Li, Yinfang Sun, Jiao Liu, Luhua Jin, Xian Shao, Mingzhen Pang, Licong Su, Fan Luo, Xin Xu, Fan Fan Hou   +12 more
doaj   +1 more source